iFRET | QF-Pro Glossary

View

Definition

immune-FRET (iFRET) is an adaptation of FLIM-FRET methodology specifically designed to measure receptor-ligand interactions occurring across cell membranes–such as PD-1 on T-cells binding PD-L1 on tumor cells. iFRET detects these intercellular interactions at 1–10 nm resolution, revealing functional checkpoint engagement that expression-based assays cannot detect.

Video Segments

JCO Clinical Study: 188 NSCLC Patients

Primary

Intercellular detection

Cross-membrane interactions

Immune-tumor interface

T-cell to cancer cell

Quantitative output

FRET efficiency %

Violet 3.0

Clinically validated

Predicts IO response

n=176 melanoma

The Intercellular Challenge

Immune checkpointLoading... interactions occur at the immune synapse–the interface between immune cells and their targets. PD-1 on T-cells binds PD-L1 on tumor cells; CTLA-4 competes with CD28 for binding to CD80/CD86 on antigen-presenting cells.

These interactions span the gap between two cell membranes (~15–20 nm). The receptor-ligand binding itself occurs at distances of 1–10 nm–exactly the FRET detection range. iFRET is therefore perfectly suited to detect functional checkpoint engagement.

expression-based assayLoading...s tell you "PD-L1 is present on tumor cells" and "PD-1 is present on T-cells." iFRET tells you "PD-1 and PD-L1 are functionally engaged, actively suppressing immune response."

Simplified

What Makes It Different: iFRET measures interactions between proteins on DIFFERENT cells—like checkpoint molecules at the immune synapse between a T cell and tumor cell.

The Technical Hurdle: Cells must actually be in contact, and both proteins must be labeled. This is more complex than measuring interactions within a single cell.

Clinical Validation Data

In a study of 176 metastatic melanoma patients, iFRET-measured PD-1/PD-L1Loading... interaction state directly correlated with overall survival (p=0.05), while PD-L1 expression by IHCLoading... showed no predictive value (p=0.87).

Critically, in 11 PD-L1-negative patients by conventional IHC, iFRET detected checkpoint interaction in 10 patients–patients who would have been deemed ineligible for checkpoint blockade by standard criteria but who showed evidence of active checkpoint engagement.

This finding validates the paradigm shift from expression-based to function-based biomarkers: low expression does not mean absence of function.

Simplified

Proven Applications:

• PD-1/PD-L1: 176 melanoma patients—engagement predicted survival (P=0.05), expression didn't (P=0.87)

• CTLA-4/CD80: First-ever measurement at 1-10nm resolution in patient tissue

Both demonstrated that functional engagement provides different information than expression.

Clinical Applications

Clinically Validated

Validated Checkpoint Pairs: iFRET has been clinically validated for measuring intercellular checkpoint interactions including PD-1/PD-L1 and CTLA-4/CD80 in FFPE tissue from multiple cancer types.

In the neoadjuvant TVEC melanoma study (2025), complete responders showed significantly increased iFRET efficiency post-treatment, while non-responders showed unchanged values–differences not captured by PD-L1 expression scoring.

Simplified

Clinical proof: iFRET is validated for measuring PD-1/PD-L1 and CTLA-4/CD80 interactions in standard pathology tissue. In melanoma patients receiving TVEC therapy, responders showed increased checkpoint engagement–a change invisible to expression testing.

Clinical Impact

Identifies checkpoint blockade responders among PD-L1-low patients
Quantifies heterogeneity in checkpoint engagement across tumor regions
Enables rational selection of checkpoint inhibitorLoading... combinations based on functional engagement

Connected Terms

FLIM Category Cross-ref Related Learning Path
QF-Pro Category Cross-ref Related Learning Path
FRET Category Cross-ref Related Learning Path
PD-1/PD-L1 Cross-ref Related Video
Biomarker Validation Cross-ref Related Video
NSCLC Cross-ref Related Video
FLIM-FRET Category Cross-ref Related
Immune Checkpoint Cross-ref Related